Further, the investigator could withdraw the patient from the study at any time and administer the NK-1 receptor antagonist aprepitant with subsequent chemotherapy cycles
Further, the investigator could withdraw the patient from the study at any time and administer the NK-1 receptor antagonistaprepitant with subsequent chemotherapy cycles